Renalytix AI plc Total Assets 2011-2026 | RNLX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Renalytix AI plc

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
7.97 M	30.6 M	50.1 M	78.6 M	20.9 M	9.7 M	56.6 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
78.6 M	56.6 K	28.3 M

Quarterly Total Assets Renalytix AI plc

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.79 M	7.97 M	8.77 M	11.3 M	19.5 M	30.6 M	-	-	-	-	44.5 M	54.4 M	-	78.6 M	-	-	-	20.9 M	-	-	-	9.7 M	-	-	-	115 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
78.6 M	115 K	24.3 M

Total Assets of other stocks in the Diagnostics research industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	10.7 B	$ 115.69	0.13 %	$ 35.2 B	USA
Akumin AKU	1.77 B	-	-17.87 %	$ 25.9 M	Canada
Illumina ILMN	6.3 B	$ 128.66	0.61 %	$ 20.5 B	USA
Accelerate Diagnostics AXDX	65 M	-	-61.36 %	$ 2.46 M	USA
Co-Diagnostics CODX	24.7 M	$ 1.66	-0.9 %	$ 2.21 M	USA
Aspira Women's Health AWH	5.46 M	-	-6.19 %	$ 10.5 M	USA
Lantheus Holdings LNTH	2.23 B	$ 84.24	-0.11 %	$ 5.69 B	USA
Medpace Holdings MEDP	1.98 B	$ 417.83	1.78 %	$ 12.1 B	USA
Biocept BIOC	30.9 M	-	-13.05 %	$ 7.29 M	USA
Castle Biosciences CSTL	531 M	$ 24.81	1.43 %	$ 689 M	USA
Chembio Diagnostics CEMI	62.6 M	-	0.22 %	$ 16.8 M	USA
Koninklijke Philips N.V. PHG	26.9 B	$ 27.56	0.31 %	$ 20 B	Niderland
Check-Cap Ltd. CHEK	377 K	-	-	$ 9.42 M	Israel
CareDx, Inc CDNA	413 M	$ 21.33	0.47 %	$ 1.14 B	USA
Oxford Immunotec Global PLC OXFD	235 M	-	-	$ 562 M	Britain
Senseonics Holdings SENS	126 M	$ 7.17	1.7 %	$ 299 M	USA
DermTech DMTK	122 M	-	-11.32 %	$ 2.94 M	USA
Soleno Therapeutics SLNO	564 M	$ 52.75	0.06 %	$ 2.68 B	USA
Enzo Biochem ENZ	85.8 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	5.86 B	-	-	$ 19.8 B	USA
Fulgent Genetics FLGT	1.22 B	$ 15.7	-3.74 %	$ 475 M	USA
Global Cord Blood Corporation CO	8.53 B	-	-	$ 399 M	China
Thermo Fisher Scientific TMO	110 B	$ 467.48	-0.45 %	$ 176 B	USA
Fluidigm Corporation FLDM	325 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	20.8 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	975 M	-	0.12 %	$ 80.1 M	China
Trinity Biotech plc TRIB	103 M	$ 0.64	-0.83 %	$ 61.9 M	Irlanda
Charles River Laboratories International CRL	7.14 B	$ 171.6	1.08 %	$ 8.51 B	USA
PRA Health Sciences, Inc. PRAH	4.18 B	-	-	$ 10.7 B	USA
Twist Bioscience Corporation TWST	642 M	$ 61.18	0.39 %	$ 3.66 B	USA
Guardant Health GH	2.01 B	$ 89.01	0.11 %	$ 11.2 B	USA
HTG Molecular Diagnostics HTGM	17.8 M	-	-20.0 %	$ 1.06 M	USA
Heska Corporation HSKA	586 M	-	-	$ 1.31 B	USA
Interpace Biosciences IDXG	33.8 M	$ 1.93	-2.08 %	$ 8.54 M	USA
Motus GI Holdings MOTS	7.22 M	-	-34.28 %	$ 263 K	Israel
QIAGEN N.V. QGEN	6.28 B	-	-	$ 10.6 B	Niderland
Neogen Corporation NEOG	3.44 B	$ 9.58	0.42 %	$ 2.08 B	USA
Biomerica BMRA	5.94 M	$ 2.15	0.7 %	$ 4.94 M	USA
National Research Corporation NRC	135 M	$ 17.19	-0.23 %	$ 385 M	USA
ICON Public Limited Company ICLR	16.9 B	$ 101.81	-0.35 %	$ 8.4 B	Irlanda
Laboratory Corporation of America Holdings LH	18.4 B	$ 263.75	-	$ 21.9 B	USA
Celcuity CELC	467 M	$ 124.21	2.62 %	$ 5.81 B	USA
OpGen OPGN	9.86 M	-	-16.95 %	$ 1.54 M	USA
NeoGenomics NEO	1.36 B	$ 8.48	2.29 %	$ 1.09 B	USA
Myriad Genetics MYGN	707 M	$ 4.79	0.21 %	$ 444 M	USA
Natera NTRA	1.39 B	$ 204.22	0.23 %	$ 20.1 B	USA
Quest Diagnostics Incorporated DGX	16.2 B	$ 196.35	0.07 %	$ 21.8 B	USA
Invitae Corporation NVTA	1.95 B	-	-	$ 21.2 M	USA
PerkinElmer PKI	12.2 B	-	-0.91 %	$ 14.7 B	USA